Netherlands vs Zambia: The number of people with susceptibility test result for rifampicin
Netherlands
86.26
in 2021
Zambia
85.35
in 2021
Netherlands rank
82nd
Zambia rank
84th
The number of people with susceptibility test result for rifampicin over time
- Netherlands
- Zambia
How they compare
Netherlands currently reports 86.26 against 85.35 in Zambia, a difference of 0.91.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Netherlands ahead.
Netherlands ranks 82nd and Zambia ranks 84th of 146 countries.
Across the 2 decades both report, Netherlands averaged higher in 1 and Zambia in 1.
Head to head by decade
| Decade | Netherlands | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 88.98 | 65.88 | 23.1 | Netherlands |
| 2020s | 86.86 | 88.01 | 1.15 | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Netherlands or Zambia?
- Netherlands, at 86.26 against 85.35 in Zambia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Netherlands and Zambia?
- 0.91, with Netherlands ahead.
- How many years of comparable data are there for Netherlands and Zambia?
- 5 years are reported by both, from 2017 to 2021.
- How do Netherlands and Zambia rank globally for the number of people with susceptibility test result for rifampicin?
- Netherlands ranks 82nd and Zambia ranks 84th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.